Mesoblast on go with study of remestemcel-L in COVID-19 (NASDAQ:MESO)

Mesoblast’s (NASDAQ:MESO) remestemcel-L will be evaluated in a placebo-controlled trial in 240 patients with acute respiratory distress syndrome (ARDS) caused by COVID-19.

This Phase 2/3 trial will be conducted as a public-private partnership in collaboration with the Cardiothoracic Surgical Trials Network, established by the U.S. National Institutes of Health’s National Heart, Lung and Blood Institute as a flexible platform for conducting collaborative trials.

Facebook Comments

Leave a Reply

Your email address will not be published. Required fields are marked *